Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 33.29% is 184% above its 5-year average of -39.80%, near the high end of its 5-year range (-58.32%–33.29%).
236.24% above its 12-month average of -24.43%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 9.21%.
RETURN ON ASSETS (ROA)
33.29%
RETURN ON ASSETS (ROA) AVG TTM
-24.43%
RETURN ON ASSETS (ROA) AVG 3Y
-40.18%
RETURN ON ASSETS (ROA) AVG 5Y
-39.80%
RETURN ON ASSETS (ROA) AVG 10Y
-39.23%
RETURN ON ASSETS (ROA) AVG 15Y
-28.52%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+236.24%
CURRENT VS 3Y AVG
+182.86%
CURRENT VS 5Y AVG
+183.63%
CURRENT VS 10Y AVG
+184.85%
CURRENT VS 15Y AVG
+216.71%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-20.55%
median of 340 covered companies
CURRENT VS SECTOR MEDIAN
+261.96%
vs the sector median at left
Ascendis Pharma A/S
Market Cap
$14.16B
Return on Assets (ROA)
33.29%
TTM Avg
-24.43%
3Y Avg
-40.18%
5Y Avg
-39.80%
Market Cap
$14.64B
Return on Assets (ROA)
-10.75%
TTM Avg
-43.49%
3Y Avg
-42.71%
5Y Avg
-41.26%
Market Cap
$14.79B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$14.97B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
Market Cap
$13.19B
Return on Assets (ROA)
6.18%
TTM Avg
14.27%
3Y Avg
15.75%
5Y Avg
18.01%
Market Cap
$15.24B
Return on Assets (ROA)
10.07%
TTM Avg
7.10%
3Y Avg
8.43%
5Y Avg
7.35%
Market Cap
$12.95B
Return on Assets (ROA)
-57.20%
TTM Avg
-68.10%
3Y Avg
-82.79%
5Y Avg
-75.08%
Market Cap
$12.89B
Return on Assets (ROA)
2.01%
TTM Avg
3.05%
3Y Avg
3.16%
5Y Avg
3.84%
Market Cap
$12.52B
Return on Assets (ROA)
-5.37%
TTM Avg
-3.64%
3Y Avg
-1.62%
5Y Avg
0.47%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 33.29% | -24.43% | -40.18% | -39.80% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -10.75% | -43.49% | -42.71% | -41.26% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 34.50% | 22.59% | 17.42% | 13.40% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | -3.17% | -0.94% | 2.58% | 3.75% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 6.18% | 14.27% | 15.75% | 18.01% |
| Solventum Corporation (SOLV)vs › | $15.24B | 10.07% | 7.10% | 8.43% | 7.35% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | -57.20% | -68.10% | -82.79% | -75.08% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 2.01% | 3.05% | 3.16% | 3.84% |
| Baxter International Inc. (BAX)vs › | $12.52B | -5.37% | -3.64% | -1.62% | 0.47% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 8.13% | 5.32% | 4.08% | 2.47% |
ROA
33.3%
ROE
53.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -16.82% |
| 2024-12-31 | -32.05% |
| 2023-12-31 | -58.32% |
| 2022-12-31 | -53.52% |
| 2021-12-31 | -35.36% |
| 2020-12-31 | -42.76% |
| 2019-12-31 | -32.22% |
| 2018-12-31 | -40.79% |
| 2017-12-31 | -58.72% |
| 2016-12-31 | -36.04% |
| 2015-12-31 | -24.98% |
| 2014-12-31 | -16.46% |
| 2013-12-31 | 15.28% |
| 2012-12-31 | 4.92% |
| 2011-12-31 | 0.00% |
